Conditions: Pulmonary Disease, Chronic Obstructive
Keywords: GW642444 COPD Fluticasone Furoate
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 187
Healthy volunteers: no

Brief summary:
The primary purpose of the study is to evaluate the safety and tolerability of fluticasone furoate/GW642444 inhalation powder when administered once-daily for 52 weeks in Japanese patients with COPD.

Detailed description:

Arms:
arm 1: Combination inhaled corticosteroid and long-acting beta2-agonist arm 2: Combination inhaled corticosteroid and long-acting beta2-agonist

Interventions: intervention 1: Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg intervention 2: Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg
Intervention descriptions: intervention 1: Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks intervention 2: Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks

Protocol document: